StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd

Bullboard Posts

Comment by TheDudeAbideson Jun 28, 2019 9:24pm

132 Views

Post# 29875435

RE:RE:RE:RE:It's been seven buisness days since James said 7-10 days

Agreed, great post.

Im with you CBG, as long as we have an agreement with a top 10 health group in the US we should have nothing to worry about.

I think the promise of Arstotle really plays into all of this, I think they actually sign whover they do based on this test. The sooner they validate Aristotle, the closer we are to Nasdaq.

Bullboard Posts

Changing Europe’s dependency on HREE from China